Can India’s pharma giant become a global obesity drug disruptor?

🚨 Investor Watchout: - Regulatory delays in key markets (e.g., Canada, US) could impact timelines. - Pricing pressure in generics, especially in the US, remains a structural risk. - R&D expenses may rise before monetization of biosimilars and complex generics. 📌 Major Key Points: - Strong pipeline in biosimilars and complex generics. - Focus on GLP-1 (semaglutide) for diabetes/obesity—potential blockbuster. - Expanding presence in emerging markets and India’s domestic formulation business. 🚀 Future Growth Planning: - Targeting global obesity and diabetes markets via GLP-1 generics. - Scaling up API exports and contract manufacturing. - Strategic acquisitions in specialty and OTC segments. 🧭 Strategy Outlook: - R&D-led growth with focus on high-margin complex molecules. - Diversification across geographies to reduce US dependency. - Digital transformation in supply chain and patient engagement.